The use of pramipexole in Parkinson's disease: are its actions D3 mediated?
- 1 July 2001
- journal article
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 7 (3) , 231-234
- https://doi.org/10.1016/s1353-8020(00)00062-6
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Parkinson's DiseaseNew England Journal of Medicine, 1998
- Parkinson's DiseaseNew England Journal of Medicine, 1998
- Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuationsNeurology, 1996
- Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's diseaseNeurology, 1996
- Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptorsEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Fortnightly Review: Drug treatment of Parkinson's diseaseBMJ, 1995
- A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's diseaseMovement Disorders, 1994
- Treatment of Parkinson's DiseaseNew England Journal of Medicine, 1993
- Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonistEuropean Journal of Pharmacology, 1992
- Bromocriptine in ParkinsonismBMJ, 1974